



# Biallelic Variant in *SERPING1* Associated with Intellectual Disability in a Consanguineous Pakistani Family

Fareeha Fatima<sup>1\*</sup>, Muhammad Asad Usmani<sup>2,4,5</sup>, Neelam Fatima<sup>1</sup>,  
Amama Ghaffar<sup>1,5</sup>, Tanveer A Qaiser<sup>3</sup>, Asma Ali Khan<sup>1\*</sup> and Saima Riazuddin<sup>5</sup>

<sup>1</sup>Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan

<sup>2</sup>Jinnah Burn and Reconstructive Surgery Centre, Allama Iqbal Medical College, University of Health Sciences, Lahore 54550, Pakistan

<sup>3</sup>Department of Molecular Biology, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, 44000, Pakistan

<sup>4</sup>Department of Biotechnology, Kohsar University, Muree, 47180, Pakistan

<sup>5</sup>Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA

## ABSTRACT

The complement system is part of humoral, innate humor immune system, which enhance the ability of antibodies and phagocyte cells to clear microbes and damage cells from an organism. It plays a crucial role in brain development, neurogenesis, neural migration, and synaptic refining. Pathogenic variants in genes, including *SERPING1*, of complementary pathways are associated with psychosis and schizophrenia. The *SERPING1* encodes highly glycosylated serine protease inhibitor C1INH, which inhibits proteins of both the classical lectin pathways of the complement system and protein that plays a key role in the complement system pathway. Here, we report a biallelic missense variant (c.5 C>T; p.(Ala2Val)) in *SERPING1* segregating with severe intellectual disability (ID), hypotonia, psychomotor and speech delay in consanguineous Pakistani kindred. The p.(Ala2Val) variant is predicted pathogenic by various in silico algorithms and replaces an evolutionary conserved residue. *SERPING1* is known to interact with *PTX3*, *MASPI*, and *C1QB* genes, variants of which have been associated with ID in humans. Our study expands the genetic repertoire of variants responsible of ID in the Pakistani population.

## Article Information

Received 23 July 2024

Revised 25 December 2024

Accepted 06 January 2025

Available online 12 June 2025

(early access)

Published 23 February 2026

## Authors' Contribution

FF: Formal analysis, investigation, methodology, visualization, writing original manuscript. MUA: Investigation, writing review & editing. NF: Investigation. AG: Investigation, writing review & editing. TAQ: Resources, AAK: Conceptualization, supervision, writing review & editing. SR: Conceptualization, funding acquisition, supervision, writing review & editing.

## Key words

Intellectual disability, Synaptic refining, Autosomal recessive, Whole exome sequencing, C1INH, Hypotonia

## INTRODUCTION

The role of immunological and inflammatory factors has been associated with psychosis and schizophrenia (Goldsmith *et al.*, 2016). The complement system, a crucial component of the inflammatory response, has also been extensively studied in this context (Kopczynska *et al.*, 2019). The complement system is the cascade of soluble proteins that are released by a number of cell types

including, hepatocytes, leucocytes, adipocytes, and neural cells (neurons, astrocytes, and microglia) in the central nervous system (Bajic *et al.*, 2015; Veerhuis *et al.*, 2011). These soluble proteins and zymogens recognize the pathogen and extrinsic antigens and initiate opsonization, pathogen phagocytosis, and anaphylatoxin activity (Bajic *et al.*, 2015; Ricklin *et al.*, 2010). The system is classified into three separate pathways- classical, lectin, and alternative- depending on their mode of activation. Curiously, all the pathways converge at factor C3 cleavage and complement effector fragments. The system is strictly regulated and specified to protect the host cells from autoimmune response (Coulthard *et al.*, 2018). Evidently, all components of the complement system are expressed in the brain and play a key role in the brain development, neural migration (Gorelik *et al.*, 2017), neurogenesis (Coulthard *et al.*, 2017; Rahpeymai *et al.*, 2006) and synaptic refining (Schafer *et al.*, 2012; Stephan *et al.*, 2012).

Genomic data-based analysis of case vs control study

\* Corresponding author: Fareeha.fatima@cemb.edu.pk, asma.ali@cemb.edu.pk  
0030-9923/2026/0002-0893 \$ 9.00/0



Copyright 2026 by the authors. Licensee Zoological Society of Pakistan.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

of 1000 psychosis individuals show *SERPING1* variant harboring individuals have reduced intelligence quotient as compared to other 90 genes associated with psychosis (Holland *et al.*, 2019). The *SERPING1* encodes highly glycosylated serine protease enzyme C1INH (C1 inhibitor) that inhibits C1r and C1s, the initial components of the classical complement system pathway. C1INH is known to interact with and modulate the activity of *MASPI/MASP2*, a protein involved in the lectin pathway for complement activation (Par  j *et al.*, 2013; Presanis *et al.*, 2004; Ricklin *et al.*, 2010). Here, we present evidence of a biallelic missense mutation in *SERPING1* that segregates with severe intellectual disability (ID), hypotonia, and delayed speech in a Pakistani consanguineous family.

## MATERIALS AND METHODS

Family PKMR442 was enrolled from Multan city of Punjab province of Pakistan, after obtaining written informed consent from all the participants. Affected individuals underwent examinations by a neurologist and primary physician to assess specific features associated with ID, behavior, neurological and motor delays, ophthalmological, auditory, and skeletal abnormalities.

**Table I. ES analysis of family PKMR 442.**

| Exome sequencing data                                                    | PKMR222 individual IV-1 |
|--------------------------------------------------------------------------|-------------------------|
| Total mapped read (Gbp)                                                  | 5-6                     |
| Target coverage (%)                                                      | 96-97                   |
| Mean depth of coverage (x)                                               | 65-80                   |
| Depth >20 x coverage (%)                                                 | 80-90                   |
| Total changes                                                            | 285384                  |
| Non-synonyms/insertion/deletion/splice site                              | 57489                   |
| Changes <0.01% allele frequency in 1000 genome/NHLBI exome/ExAC database | 20171                   |
| Changes not found in Pakistani control sample populations                | 12009                   |
| Genes with homozygous/compound heterozygous changes                      | 301                     |
| Missense/indels/splice variants                                          | 59                      |
| Changes predicted to be pathogenic                                       | 11                      |
| Gene with nucleotide variation in more than one affected individual      | 1                       |
| Changes co segregating with the phenotype in the family                  | 1                       |


Blood samples were collected for DNA extraction using the inorganic method (MWER *et al.*, 1988). ES (exome sequencing) was performed on the DNA sample of

the proband (IV:3) at the University of Maryland and the *SERPING1* variant was identified by using exome filtering criteria as described previously (Usmani *et al.*, 2024). Furthermore, Sanger sequencing was performed using gene-specific primers to confirm the co-segregation of the *SERPING1* variant with the ID phenotype in the family. *In silico* analyses were performed using the Varsome, SMART, AlphaFold2 Clustal Omega, and Allen Brain Atlas.

## RESULTS

### Clinical data

According to the medical evaluation, all three affected individuals (IV:1, IV:3 & IV:7) of PKMR442 (Fig. 1A, B) have severe ID (HP:0010864), hypotonia (HP:0001252), show psychomotor (HP: 0001263) and speech delay (HP:000750) except for subject IV:7 who had no speech. Behavioral analysis presented aggressive behavior (HP: 0000718) in all the affected individuals particularly IV:3, where it was extended to self-mutilation tendency. Physical examination did not show any abnormality in the siblings IV:3 and IV:7 however, individual IV-1 had abnormal stature and bone structure of the forelimbs (Fig. 1C). No visual or hearing deficits were noted in all three affected individuals (Table II). It is also notified that no sign of angioedema was observed in the siblings of the family.



**Fig. 1. A homozygous variant in *SERPING1* segregates in PKMR 422 (A) Family pedigree of PKMR 422. Square: male, circle: female, filled symbol: affected individual, the double line between individual: consanguineous mating. + symbol: Wildtype allele, - symbol: Mutant allele (B) Gene sequence chromatograph showing the nucleotide change c. 5C>T in homozygous affected and heterozygous carriers in comparison to homozygous normal alleles. (C) Phenotypic features of the affected proband individual IV-1.**

**Table II. Clinical and genetical features of the family PKMR 442.**

| Clinical and genetical features            | PKMR 442                                    | PKMR 442             | PKMR 442            |
|--------------------------------------------|---------------------------------------------|----------------------|---------------------|
| Individual                                 | IV-1                                        | IV-3                 | IV-7                |
| Gender                                     | Male                                        | Female               | Female              |
| Age                                        | 10                                          | 19                   | 14                  |
| Ancestry                                   | Pakistani                                   |                      |                     |
| RefSeq ID                                  | NM_001032295                                |                      |                     |
| Variation                                  | c.5C>T p. (Ala2Val)                         | c. 5C>T p. (Ala2Val) | c.5C>T p. (Ala2Val) |
| Zygosity                                   | Homozygous                                  | Homozygous           | Homozygous          |
| <b>Growth features</b>                     |                                             |                      |                     |
| Weight (kg)                                | 52                                          | 68                   | 60                  |
| Height (cm)                                | 138                                         | 161                  | 145                 |
| Head circumference (cm)                    | 55.5                                        | 57                   | 54                  |
| <b>Neurological features</b>               |                                             |                      |                     |
| ID                                         | Severe                                      | Severe               | Severe              |
| Epilepsy                                   | Yes                                         | No                   | Yes                 |
| Ataxia                                     | Yes                                         | Yes                  | No                  |
| Hypotonia                                  | Yes                                         | Yes                  | Yes                 |
| Spasticity                                 | No                                          | No                   | No                  |
| Intellectual and neurological delay        |                                             |                      |                     |
| Speech delay                               | Yes                                         | Yes                  | No                  |
| Psychomotor delay                          | Yes                                         | Yes, Sluggish        | Yes                 |
| Other features/ investigations/ angioedema | Spine, rib cage and arms bones are abnormal | No                   | No                  |

**Table III. Short listed variants from exome data.**

| S. No. | Chr | Position | Ref | Alt | Func. ref gene | Gene. ref gene | ExonicFunc. ref gene | esp6500si | ExAC_ALL |
|--------|-----|----------|-----|-----|----------------|----------------|----------------------|-----------|----------|
| 1      | 1   | 2.49E+08 | G   | A   | Exonic         | OR2T3          | Nonsynonymous SNV    | .         | 0.0042   |
| 3      | 2   | 1.31E+08 | T   | A   | Exonic         | POTEI          | Nonsynonymous SNV    | .         | 0        |
| 4      | 4   | 1016071  | G   | A   | Exonic         | FGFRL1         | Nonsynonymous SNV    | .         | 0.0001   |
| 5      | 6   | 32489883 | G   | T   | Exonic         | HLA-DRB5       | Nonsynonymous SNV    | .         | 0.0002   |
| 6      | 6   | 32489940 | G   | A   | Exonic         | HLA-DRB5       | Stopgain             | .         | 0.0003   |
| 7      | 11  | 57365748 | C   | T   | Exonic         | SERPING1       | Nonsynonymous SNV    | 0.000787  | 0.0025   |
| 8      | 11  | 76922381 | G   | A   | Exonic         | MYO7A          | Nonsynonymous SNV    | .         | 0.0001   |
| 9      | 12  | 32137067 | A   | G   | Exonic         | KIAA1551       | Nonsynonymous SNV    | 0.001999  | 0.0058   |
| 10     | 15  | 41798189 | C   | T   | Exonic         | LTK            | Nonsynonymous SNV    | 0.000154  | 0.0001   |
| 11     | 16  | 69876022 | C   | T   | Exonic         | WWP2           | Nonsynonymous SNV    | .         | 0.0002   |
| 12     | 17  | 30980871 | T   | A   | Exonic         | MYO1D          | Nonsynonymous SNV    | 0.002307  | 0.0025   |

*Variant identification and molecular modeling*

A homozygous missense variant c.5 C>T p.(Ala2Val) in *SERPING1* (NM\_001032295) gene was identified in proband IV:3 through ES (Table III). A total of 11 gene variations (SNV) were short-listed after the analysis of the exome-sequenced data (Table III). Sanger sequencing

confirmed homozygosity of only *SERPING1* variant in all three affected individuals, while parents were obligatory carriers (Fig. 1). Unaffected siblings IV:4, IV:5, and IV:6 were also heterozygous while individual IV:2 was homozygous wild type (Fig. 1).

**Table IV. *In Silico* single nucleotide variation functional prediction of *SERPING1*.**

| <i>In silico</i> SNV analysis | Findings          |
|-------------------------------|-------------------|
| Hg19 coordinates              | Chr11:57365748    |
| Nucleotide variation          | c.5C>T            |
| Amino acid variation          | p. (Ala2Val)      |
| RefSeq                        | NM_001032295      |
| ExAC frequency                | 0.00125           |
| gnomAD frequency              | 0000894           |
| CADD phred                    | 24.1              |
| REVEL                         | 634               |
| M-CAP                         | Damaging          |
| PolyPhen-2 HumDiv             | Possibly damaging |
| Polyphen-2 Hum Var            | Possibly damaging |
| GERP ++                       | 1.84              |
| PhyloP 1000 way vertebrate    | 1.57              |
| Mutation assessor_pred        | Uncertain         |
| MutationTaster_pred           | Polymorphism      |
| FATHMM_pred                   | Damaging          |

The c.5C>T had very low allele frequency in the gnomAD database with a CADD score of 24.1 (Table IV). According to C-MAP and Polyphen-2, the variation could possibly be damaging in nature. According to the Mutation Taster *SERPING1* protein, containing the identified variation is predicted to be polymorph. While according to FATHMM the variation is predicted to be damaging to the protein with a -2.44 score (Table IV).

Serpin Peptidase inhibitor, clade G, member 1 (*SERPING1*) encodes protease inhibitory protein C1INH. The gene is located on the long arm of chromosome 11 (11q12.1), comprising 8 exons as represented by grey shaded boxes in the schematic model diagram (Fig. 2A). SMART predicted the C1 inhibitor (C1INH) protein to contain a 22-amino-acid (AA)-long signal peptide followed by a single structured domain called SERPIN depicted in blue/grey from 136 to 498 AA. The area of complexity is also shown in pink (Fig. 2B). The p.(Ala2Val) variation is situated in the signal peptide of the encoded protein, which is indicated via an arrow in the illustration. The sole functionally defined SERPIN domain uses its reactive centre loop (RCL) to interact with the target proteins of the complement system (Fig. 2B). The evolutionary conservation of the amino acid in different species was confirmed by performing multiple amino acid sequence alignments of orthologous proteins through Clustal Omega (Fig. 2C). AlphaFold 2 confirmed the mutated region to lie

in the non-structural region of the protein with a pLDDT score of 35.5 (Fig. 2E); however, the missense alpha heatmap predicts the p.(Ala2Val) to be likely pathogenic (having a 0.72 score).

We researched the available literature and used “STRING” tool to extract all reported protein-protein interactions and noted the direct interaction of *SERPING1* with *PTX3*, *MASPI1*, and *CIQBP* (Fig. 2D) (Szkarczyk *et al.*, 2023). Variants of *PTX3*, *MASPI1*, and *CIQBP* genes have been previously reported in individuals with ID (Feichtinger *et al.*, 2017; Rooryck *et al.*, 2011). Our analysis from Allen Brain Atlas also shows a high expression of *SERPING1* in the human developing brain, which overlaps with these known interactors.




Fig. 2. Molecular Structure Modeling of *SERPING1* (A) Schematic representation of human *SERPING1* gene including the position of the nucleotide change. The grey shaded boxes represent exons of the gene. (B) Schematic representation of human *SERPING1* protein with the predicted effect of the identified variant in the study showing SERPIN domain in blue and area of complexity in pink. (C) Clustal W amino acid sequence alignment of the *SERPING1* from human, mouse, cat, monkey, lion, brown bat, chimpanzee, and bovine. The square orange box indicates the position of the mutated amino acid conserved across the vertebrates. (D) STRING analysis based on *SERPING1* protein interaction with various proteins in nature, the highlighted genes *PTX3*, *MASPI1*, and *CIQBP* are associated with ID-disorder in Humans. (E) AlphaMissense Pathogenicity Heatmap showing mutated residue p.(Ala2Val) to be likely pathogenic presented in a red colored box with the score of 0.722.

## DISCUSSION

ID refers to an individual's limitation in cognitive functioning and adaptive behavior. It is a phenotypically and genetically heterogeneous disorder with a prevalence of approximately 2.5% worldwide (Maulik *et al.*, 2011). Here, we demonstrate the role of ES approach in identifying pathogenic variant in PKMR442 family segregating ID in an autosomal recessive fashion. The

results of our studies lead us to a biallelic missense variant c.5C>T in the *SERPING1* gene which encodes C1INH with a key regulatory role in the complement system. The system is extensively studied as it is the main component of the innate immune response. The complement system is also associated with neurodevelopmental disorders, especially concerning neuronal pruning. In murine, the proteins of these pathways including C1q and C3 are localized to developing CNS synapses during periods of active synapse elimination and are required for normal brain wiring. Their functions in the brain seem to be analogous to that of the immune system involving opsonization. The synapse tagged with complement protein is eliminated by microglial cells with complement surface receptors (Stevens *et al.*, 2007). Astrocytes also induce the expression of complement proteins in the brain. In a mature brain, the loss of synapses is the trademark of several neurodegenerative disorders. Upregulation of complement pathways is suggested to play a role in neural pruning and consequent neurodevelopment disorder (Holland *et al.*, 2019).

Previously, *SERPING1* encoding C1-INH has been suggested to play a role in neuronal stem cell proliferation and activation of all three complement pathways (Gorelik *et al.*, 2017). Knockout of *SERPING1* induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits (Farfara *et al.*, 2019). *SERPING1* role is suggested in neuronal migration and brain development (Gorelik *et al.*, 2017). In a human genetic study schizophrenic (SZ) twin, showed involvement of *SERPING1* with cortical thinning of superior frontal region (Allswede *et al.*, 2018). Another study on SZ found expression of *SERPING1* in the amygdala (Chang *et al.*, 2017). Conversely, above two studies were performed in individuals with SZ, however, it is known that overall, 31.7 % of identified ID people had some sort of psychiatric disorder (Morgan *et al.*, 2008). Thus, making these studies important in our quest to understand the role of *SERPING1* in ID.

*In vivo*, studies on *SERPING1* attenuated acute neurobehavioral and degeneration deficit along with ischemic volume (Longhi *et al.*, 2009). In the gene-enriched studies of the complement pathway, out of all the gene-set, *SERPING1* is reported to be most associated with the human IQ (Holland *et al.*, 2019) which supports the pivotal role of *SERPING1* in neural development and neuroinflammatory response.

## CONCLUSION

A current study identified a homozygous missense variant in *SERPING1* in a consanguineous Pakistani

family PKMR 442 with affected siblings presenting with autosomal recessive ID, hypotonia, and speech delay.

The results of our findings are consistent with the studies that associate *SERPING1* with neurodevelopmental and cognitive functioning making it a candidate gene for elucidation of ID etiology. Hence, making it a key regulator of the complement system that inhibits the inappropriate activation of neural pruning and neuroinflammation response.

## DECLARATIONS

### Acknowledgment

This study received approval from the Institutional Review Boards at the Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan, and University of Maryland, Baltimore, USA. We would like to thank the participating individuals and their families and health care professionals involved in their care.

### Funding

This study has been supported by a grant from the National Institutes of Health (NIH) National Institute of Neurological Disorder and Stroke (NINDS) R01NS107428 to Saima Riazuddin and Higher Education Commission Pakistan through Indigenous PhD Fellowship Program to Fareeha Fatima.

### IRB statement

The study was conducted and approved by the Institutional Review Board (IRB) of the Center of Excellence in Molecular Biology, Lahore, Pakistan, and the University of Maryland, Baltimore, USA.

### Ethical statement

This study was approved by the ethics committee of Centre of Excellence in Molecular Biology, University of the Punjab Lahore (No: IRB-ID/2023), and the informed consent was obtained from guardian of the patients and all participants.

### Informed consent statement

Informed consent was obtained from all the individuals involved in the study.

### Statement of conflict of interest

The authors have declared no conflict of interest.

## REFERENCES

- Allswede, D.M., Zheutlin, A.B., Chung, Y., Anderson, K., Hultman, C.M., Ingvar, M. and Cannon, T.D.,

2018. Complement gene expression correlates with superior frontal cortical thickness in humans. *Neuropsychopharmacology*, **43**: 525-533. <https://doi.org/10.1038/npp.2017.164>
- Bajic, G., Degn, S.E., Thiel, S. and Andersen, G.R., 2015. Complement activation, regulation, and molecular basis for complement-related diseases. *EMBO J.*, **34**: 2735-2757. <https://doi.org/10.15252/embj.201591881>
- Chang, X., Liu, Y., Hahn, C., Gur, R., Sleiman, P. and Hakonarson, H., 2017. RNA-seq analysis of amygdala tissue reveals characteristic expression profiles in schizophrenia. *Transl. Psych.*, **7**: e1203-e1203. <https://doi.org/10.1038/tp.2017.154>
- Coulthard, L.G., Hawksworth, O.A., Li, R., Balachandran, A., Lee, J.D., Sepehrband, F., Kurniawan, N., Jeanes, A., Simmons, D.G. and Wolvetang, E., 2017. Complement C5aR1 signaling promotes polarization and proliferation of embryonic neural progenitor cells through PKC $\zeta$ . *J. Neurosci.*, **37**: 5395-5407. <https://doi.org/10.1523/JNEUROSCI.0525-17.2017>
- Coulthard, L.G., Hawksworth, O.A. and Woodruff, T.M., 2018. Complement: the emerging architect of the developing brain. *Trends Neurosci.*, **41**: 373-384. <https://doi.org/10.1016/j.tins.2018.03.009>
- Farfara, D., Feierman, E., Richards, A., Revenko, A.S., MacLeod, R.A., Norris, E.H. and Strickland, S., 2019. Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits. *Glia*, **67**: 1359-1373. <https://doi.org/10.1002/glia.23611>
- Feichtinger, R.G., Oláhová, M., Kishita, Y., Garone, C., Kremer, L.S., Yagi, M., Uchiumi, T., Jourdain, A.A., Thompson, K. and D'Souza, A.R., 2017. Biallelic C1QBP mutations cause severe neonatal-, childhood-, or later-onset cardiomyopathy associated with combined respiratory-chain deficiencies. *Am. J. Hum. Genet.*, **101**: 525-538. <https://doi.org/10.1016/j.ajhg.2017.08.015>
- Goldsmith, D., Rapaport, M. and Miller, B., 2016. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol. Psych.*, **21**: 1696-1709. <https://doi.org/10.1038/mp.2016.3>
- Gorelik, A., Sapir, T., Haffner-Krausz, R., Olender, T., Woodruff, T.M. and Reiner, O., 2017. Developmental activities of the complement pathway in migrating neurons. *Nat. Commun.*, **8**: 15096. <https://doi.org/10.1038/ncomms15096>
- Gorelik, A., Sapir, T., Woodruff, T.M. and Reiner, O., 2017. Serping1/C1 inhibitor affects cortical development in a cell autonomous and non-cell autonomous manner. *Front. Cell. Neurosci.*, **11**: 169. <https://doi.org/10.3389/fncel.2017.00169>
- Holland, J.F., Cosgrove, D., Whitton, L., Harold, D., Corvin, A., Gill, M., Mothersill, D.O., Morris, D.W. and Donohoe, G., 2019. Beyond C4: Analysis of the complement gene pathway shows enrichment for IQ in patients with psychotic disorders and healthy controls. *Genes, Brain Behav.*, **18**: e12602. <https://doi.org/10.1111/gbb.12602>
- Kopczynska, M., Zelek, W., Touchard, S., Gaughran, F., Di Forti, M., Mondelli, V., Murray, R., O'Donovan, M.C. and Morgan, B.P., 2019. Complement system biomarkers in first episode psychosis. *Schizophr. Res.*, **204**: 16-22. <https://doi.org/10.1016/j.schres.2017.12.012>
- Longhi, L., Perego, C., Ortolano, F., Zanier, E.R., Bianchi, P., Stocchetti, N., McIntosh, T.K. and De Simoni, M.G., 2009. C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice. *Crit. Care Med.*, **37**: 659-665. <https://doi.org/10.1097/CCM.0b013e318195998a>
- Maulik, P.K., Mascarenhas, M.N., Mathers, C.D., Dua, T. and Saxena, S., 2011. Prevalence of intellectual disability: a meta-analysis of population-based studies. *Res. Dev. Disabilit.*, **32**: 419-436. <https://doi.org/10.1016/j.ridd.2010.12.018>
- Morgan, V.A., Leonard, H., Bourke, J. and Jablensky, A., 2008. Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study. *Br. J. Psych.*, **193**: 364-372. <https://doi.org/10.1192/bjp.bp.107.044461>
- MWer, S., Dykes, D. and Polesky, H., 1988. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucl. Acids Res.*, **16**: 1215. <https://doi.org/10.1093/nar/16.3.1215>
- Paréj, K., Dobó, J., Závodszy, P. and Gál, P., 2013. The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while  $\alpha$ 2-macroglobulin is not. *Mol. Immunol.*, **54**: 415-422. <https://doi.org/10.1016/j.molimm.2013.01.009>
- Presanis, J.S., Hajela, K., Ambrus, G., Gál, P. and Sim, R.B., 2004. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. *Mol. Immunol.*, **40**: 921-929. <https://doi.org/10.1016/j.molimm.2003.10.013>
- Rahpeymai, Y., Hietala, M.A., Wilhelmsson, U., Fotheringham, A., Davies, I., Nilsson, A.K., Zwirner,

- J., Wetsel, R.A., Gerard, C. and Pekny, M., 2006. Complement: a novel factor in basal and ischemia-induced neurogenesis. *EMBO J.*, **25**: 1364-1374. <https://doi.org/10.1038/sj.emboj.7601004>
- Ricklin, D., Hajishengallis, G., Yang, K. and Lambris, J.D., 2010. Complement: a key system for immune surveillance and homeostasis. *Nat. Immunol.*, **11**: 785-797. <https://doi.org/10.1038/ni.1923>
- Rooryck, C., Diaz-Font, A., Osborn, D.P., Chabchoub, E., Hernandez-Hernandez, V., Shamseldin, H., Kenny, J., Waters, A., Jenkins, D. and Kaissi, A.A., 2011. Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome. *Nat. Genet.*, **43**: 197-203. <https://doi.org/10.1038/ng.757>
- Schafer, D.P., Lehrman, E.K., Kautzman, A.G., Koyama, R., Mardinly, A.R., Yamasaki, R., Ransohoff, R.M., Greenberg, M.E., Barres, B.A. and Stevens, B., 2012. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron*, **74**: 691-705. <https://doi.org/10.1016/j.neuron.2012.03.026>
- Stephan, A.H., Barres, B.A. and Stevens, B., 2012. The complement system: an unexpected role in synaptic pruning during development and disease. *Annu. Rev. Neurosci.*, **35**: 369-389. <https://doi.org/10.1146/annurev-neuro-061010-113810>
- Stevens, B., Allen, N.J., Vazquez, L.E., Howell, G.R., Christopherson, K.S., Nouri, N., Micheva, K.D., Mehalow, A.K., Huberman, A.D. and Stafford, B., 2007. The classical complement cascade mediates CNS synapse elimination. *Cell*, **131**: 1164-1178. <https://doi.org/10.1016/j.cell.2007.10.036>
- Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A.L., Fang, T., Doncheva, N.T. and Pyysalo, S., 2023. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucl. Acids Res.*, **51**: D638-D646. <https://doi.org/10.1093/nar/gkac1000>
- Usmani, M.A., Ghaffar, A., Shahzad, M., Akram, J., Majeed, A.I., Malik, K., Fatima, K., Khan, A.A., Ahmed, Z.M. and Riazuddin, S., 2024. A missense variant in HACE1 is associated with intellectual disability, epilepsy, spasticity and psychomotor impairment in a Pakistani kindred. *Genes*, **15**: 580. <https://doi.org/10.3390/genes15050580>
- Veerhuis, R., Nielsen, H.M. and Tenner, A.J., 2011. Complement in the brain. *Mol. Immunol.*, **48**: 1592-1603. <https://doi.org/10.1016/j.molimm.2011.04.003>